David R. Zook

Chair - Faegre Baker Daniels Consulting

Dave Zook is an advisor to the private and public sectors on federal budgetary, legislative and regulatory matters. His practice focuses on public policy and funding initiatives in the health, higher education and research arenas. In addition to serving as the managing partner of Faegre Baker Daniels' Washington, D.C. office, Dave is chair of the law firm's consulting division, Faegre Baker Daniels Consulting, where he leads the development of interdisciplinary, sector-focused services.

Dave has a two-decade record of client accomplishments with Congress and the Executive Branch. He has directed complex federal relations initiatives for private sector companies, trade and voluntary associations, hospitals, universities and local governments. Several of those projects have involved building and operating nationwide coalitions.

Dave's background includes serving as associate counsel to the U.S. House Appropriations Committee where he focused on energy research and nuclear defense matters across the National Labs. Dave also worked in legislative and communications positions for two members of Congress. Later, he served as a senior executive of a national health organization where he established a public policy group.

Dave serves clients of Faegre Baker Daniels Consulting as a consulting professional, and does not act as a lawyer for those clients. Separately, Dave serves other clients as a lawyer for Faegre Baker Daniels LLP. He can help you decide which services are best for you. Learn more.

Federal Positions

  • U.S. House Committee on Appropriations
  • U.S. Representative John T. Myers
  • U.S. Representative Elwood Hillis

Professional Associations

  • District of Columbia Bar Association
  • American Bar Association

Civic Activities

  • National Forum for Heart Disease and Stroke Prevention — Past Chair
  • Consortium for Southeastern Hypertension Control — Board Member
  • National Association of Graduate-Professional Students — National Advisory Board (Chair)


  • Specialty Care in the World of Value — A New Reality
    Moderator, Ochsner Value Summit, New Orleans, LA, November 2017
  • National Opioids Policy Discussion Forum
    Co-facilitator, USP, Washington, D.C., August 2017
  • Medication-Assisted Treatment Access Roundtable
    Co-facilitator, Collaborative for Effective Prescription Opioid Policies, Washington, D.C., July 2017
  • Breakthrough! Walking the Thin Line Between Hope, Hype and Heartbreak in the Patient Community
    Co-presenter, FasterCures Patients Count Academy Webinar, Washington, D.C., June 2017
  • White House, Congress and Health Care: What to Expect
    Keynote presenter, National Physician Advisors Conference, Greenville, SC, April 2017
  • Federal Changes Impacting the Delivery of Treatment for Opioid Use Disorder
    Co-presenter, National Rx Abuse Summit, Atlanta, GA, April 2017
  • Roundtable on Safe Opioid Use in the Acute Care Setting
    Co-facilitator, CEPOP-BD, Washington, D.C., March 2017
  • Health on the Hill
    The ALS Association Advocacy Fly-In, Washington, D.C., February 2017
  • Access to Emerging Therapies Forum
    Parent Project Muscular Dystrophy Annual Advocacy Conference, Washington, D.C., February 2017
  • The Potential Impact of a New Administration on CMMI
    COSEHC Practice Transformation Network Annual Meeting, Tampa, February 2017
  • Building a Culture of Health at the Community Level
    National Forum Annual Conference for Heart Disease & Stroke Prevention, Washington, D.C., October 2016
  • The Impact of Patient Input on R&D
    Panelist, Colorado Life Science Innovation Forum, Denver, August 2016
  • Patient Facilitated Drug Development
    Moderator, Boston Children’s Hospital Advocacy Series, July 016
  • Patient Engagement in the FDA Process
    Co-presenter, Food and Drug Law Institute Annual Conference, May 2015
  • Creating an FDA Guidance Document for ALS Drug Development
    Co-presenter, ALS Association Collaboration for a Cure, April 2015

Published Articles


Transmission of information to us via this feature does not establish an attorney-client relationship. Do not send any information that you would have treated confidentially.